Crown Bioscience & MBL Co., Ltd.
Crown Bioscience & MBL Co., Ltd. launches large-scale organoid panel screening platform “OrganoidXplore(TM)” in Japan
～Results from 50 organoid models will triple the development of cancer drugs～ ……
San Diego, U.S.A. Crown Bioscience Co., Ltd., a global contract research organization (CRO), and JSR Life Sciences, Inc. announced the revolutionary service OrganoidXplore(TM). & MBL will also begin service expansion for the Japanese market.
This large-scale organoid panel screening platform delivers robust, highly reproducible, and clinically relevant results in record time to accelerate preclinical cancer therapy drug discovery and cancer therapy development. gives researchers the power to reshape the landscape.
Screening of large panels of patient-derived organoids is made possible using Crown Bioscience’s proprietary assay-ready (AR) organoid technology. Recent posters presented at the AACR Annual Meeting and ANE International Conference 2023 demonstrate the performance of assay-ready organoids versus freshly prepared organoids using traditional methodologies. This study demonstrated the usefulness of OrganoidXplore(TM) and clarified the following items. Features of OrganoidXplore(TM)
Robust and highly reproducible
Both assay-ready and original methods can demonstrate consistently high precision across multiple assays
Shorter timelines and lower costs
OrganoidXplore(TM) can reduce project schedules by two-thirds compared to standard methods
Reliable and reproducible drug response comparisons
Both methods can show similar results in cell viability (CTG) and high content imaging (HCI) assays when tested with standard drugs such as paclitaxel, carboplatin, and cisplatin
OrganoidXplore(TM) transcends the limitations of traditional 2D cell culture systems in terms of patient relevance and represents a major leap forward in preclinical drug screening. By accurately replicating the genomic, morphological, and pathophysiological characteristics of the original tumor, researchers can screen against a wide range of predictive models.
Results are obtained in as little as 6 weeks, accelerating research speed by 3x and delivering on the robustness and reproducibility of advanced assay-ready technology.
What is possible with OrganoidXplore(TM)
Researchers can choose between a comprehensive Full Panel or a KRAS Panel focused on specific goals.
The Full Panel currently consists of 50 organoid models covering seven cancer indications, which are also available as companion PDXs (patient-derived xenografts).
The KRAS Panel specifically targets four cancer indications and covers a wide range of KRAS mutations in 25 models. These models are also available as PDX, allowing seamless transition to subsequent exams. OrganoidXplore(TM), combined with comprehensive next-generation sequencing (NGS) features including whole exome sequencing (WES) and RNA sequencing (RNAseq), enables rapid biomarker identification and highly relevant mechanisms of action. research, selection of indications and models, consideration of drug repurposing, and improved patient stratification.
-Comment from Crown Bioscience Co., Ltd.-
Senior Vice President, In Vitro, Head of Crown Bioscience Netherlands Dr. Leo Price
OrganoidXplore(TM) meets the demanding demands of pioneering research initiatives by offering a diverse selection of models covering a wide range of genetic backgrounds and mutations. Thanks to innovative organoid cryopreservation technology and assay automation, the accuracy, speed, and reproducibility of OrganoidXplore(TM) is unrivaled.
Crown Bioscience remains committed to driving innovation in oncology research, as demonstrated by the introduction of OrganoidXplore(TM), designed with a mission to accelerate drug discovery.
■About Crown Bioscience Co., Ltd.
Crown Bioscience, a subsidiary of JSR Lifesciences, is a global CRO that provides preclinical and translational platforms to support customers advancing research and development in cancer and cancer immunology.
Crown Bioscience is the only preclinical CRO offering tumor organoid services using the proven Hubrecht Organoid Technology, offering over 600 organoid models across 22 cancer indications. Additionally, we have developed the world’s largest commercially available PDX collection. Crown Bioscience is focused on helping its customers develop novel treatments to maximize the opportunity for patients to receive the right treatment at the right time. Founded in 2006, Crown Bioscience has 13 facilities across the United States, Europe, and Asia.
■About Crown Bioscience & MBL Co., Ltd.
Crown Bioscience’s Japanese subsidiary is a contract drug development organization (CRO) that globally provides preclinical and
translational platforms to promote drug discovery in oncology and cancer immunology.
In order to expand Crown Bioscience’s preclinical services in Japan, we will launch the service in September 2022 as a joint venture with MBL (Medical and Biological Research Institute, Inc., a group company in the life science business of JSR Corporation). We have started offering.
For more information and inquiries, please visit https://crownmbl.co.jp/
This article was partly generated by AI. Some links may contain Ads. Press Release-Informed Article.